AtriCure (NASDAQ:ATRC) is a medical device company focused on developing, manufacturing, and selling innovative surgical devices designed to provide solutions for physicians treating atrial fibrillation and related conditions. Specializing in minimally invasive and open surgical ablation procedures, AtriCure aims to enhance patient outcomes by providing innovative technologies that meet the needs of cardiothoracic surgeons and patients alike. The company's portfolio includes a variety of devices and accessories used in surgery that address the growing global demand for less invasive medical treatments. AtriCure's primary mission is to reduce the worldwide prevalence of atrial fibrillation by improving existing treatment options and by investing in the development of new technologies that can offer better solutions for patients and healthcare providers.